Currently, there are 3.10B common shares owned by the public and among those 3.10B shares have been available to trade.
The company’s stock has a 5-day price change of 0.80% and 19.30% over the past three months. AZN shares are trading 15.08% year to date (YTD), with the 12-month market performance up to 17.57% higher. It has a 12-month low price of $62.75 and touched a high of $87.68 over the same period. AZN has an average intraday trading volume of 5.18 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.91%, 9.27%, and 0.57% respectively.
Institutional ownership of Astrazeneca plc ADR (NASDAQ: AZN) shares accounts for 16.79% of the company’s 3.10B shares outstanding.
It has a market capitalization of $233.83B and a beta (3y monthly) value of 0.42. The stock’s trailing 12-month PE ratio is 33.46, while the earnings-per-share (ttm) stands at $2.25. The company has a PEG of 3.00 and a Quick Ratio of 0.74 with the debt-to-equity ratio at 0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.21% over the week and 1.51% over the month.
Analysts forecast that Astrazeneca plc ADR (AZN) will achieve an EPS of 1.09 for the current quarter, 1.15 for the next quarter and 5.04 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 1.06 while analysts give the company a high EPS estimate of 1.06. Comparatively, EPS for the current quarter was 1.03 a year ago. Earnings per share for the fiscal year are expected to increase by 10.36%, and 11.77% over the next financial year. EPS should shrink at an annualized rate of 11.17% over the next five years, compared to 34.63% over the past 5-year period.
Deutsche Bank on their part issued Sell rating on September 13, 2024.
